文献速递妇科

卵巢癌新辅助化疗后的病理缓解及其与结局的关联:一种生存替代标志物

Pathologic response to neoadjuvant chemotherapy in ovarian cancer and its association with outcome: A surrogate marker of survival.
PubMed 文献 · Gynecol Oncol · 2023-09-14

该回顾性研究纳入133例FIGO III/IV期接受新辅助化疗的卵巢癌患者,用三级化疗反应评分(CRS)评估大网膜标本的病理缓解。CRS 3与CRS 1相比,无进展生存和总生存均改善,且该预后价值独立于BRCA状态或新辅助贝伐珠单抗使用。

要点

  • CRS 1、2、3分别见于41例(31%)、62例(47%)、30例(22%)的133例受检病例。
  • CRS 3较CRS 1的PFS延长(中位24.8 vs 12.5个月,未校正HR 0.28,95%CI 0.15-0.54,p<0.001)。
  • CRS 3较CRS 1的OS延长(中位63.3 vs 32.1个月,未校正HR 0.27,95%CI 0.10-0.68,p=0.006)。

核心结论

  • 验证了三级CRS评估卵巢癌新辅助化疗病理缓解,并证明其预后价值独立于BRCA状态或新辅助贝伐珠单抗使用。
  • 提高病理缓解率可能是卵巢癌新辅助化疗的有用目标,以期改善生存。
  • CRS可能作为卵巢癌临床试验的有用终点。

研究设计与样本

  • 回顾性研究,纳入133例FIGO III/IV期接受新辅助化疗的卵巢癌患者,使用大网膜组织标本进行CRS分级。
  • 生存分析采用单因素和多因素分析,校正年龄、FIGO分期、减瘤术和BRCA状态以及新辅助贝伐珠单抗使用。

主要发现

  • CRS 1、2、3分别见于41例(31%)、62例(47%)、30例(22%)的133例受检病例。
  • 对新辅助化疗的缓解与无进展生存(PFS,p<0.001)和总生存(OS,p=0.011)显著改善相关。
  • CRS 3较CRS 1的PFS改善:中位24.8 vs 12.5个月,未校正HR 0.28(95%CI 0.15-0.54),p<0.001;校正后HR 0.31(95%CI 0.14-0.72),p=0.007。
  • CRS 3较CRS 1的OS改善:中位63.3 vs 32.1个月,未校正HR 0.27(95%CI 0.10-0.68),p=0.006;校正后HR 0.32(95%CI 0.09-1.11),p=0.072。

关键数值与推荐

  • CRS 1为无或微小缓解,CRS 2为部分缓解,CRS 3为完全/近完全缓解。
  • CRS 3较CRS 1的PFS未校正HR 0.28(95%CI 0.15-0.54),校正后HR 0.31(95%CI 0.14-0.72)。
  • CRS 3较CRS 1的OS未校正HR 0.27(95%CI 0.10-0.68),校正后HR 0.32(95%CI 0.09-1.11)。

临床怎么用

  • 作者认为提高病理缓解率可能是卵巢癌新辅助化疗的有用目标,以期改善生存。
  • 作者认为CRS可能作为卵巢癌临床试验的有用终点。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We aimed to validate whether pathologic response (pR) to neoadjuvant chemotherapy (NACT) using a three-tier chemotherapy response score (CRS) is associated with clinical outcome in ovarian cancer (OC) and could be used as surrogate marker for survival. METHODS: We conducted a retrospective study of OC patients with FIGO stage III/IV disease who received NACT and graded response as no or minimal (CRS 1), partial (CRS 2), or complete/near-complete (CRS 3) pR using tissue specimens obtained from omentum. Uni- and multivariate survival analyses were performed accounting for age, FIGO stage, debulking and BRCA status as well as neoadjuvant use of bevacizumab. RESULTS: CRSs 1, 2 and 3 were found in 41(31%), 62 (47%) and 30 (22%) of the 133 examined cases. Response to NACT was associated with significantly improved progression-free (PFS, p < 0.001) and overall survival (OS, p = 0.011). Complete/ near-complete pathologic response (CRS3) was associated with improved PFS (median 24.8 vs. 12.5 months, unadjusted HR 0.28 [95%CI 0.15-0.54], p < 0.001; adjusted hazard ration (aHR) 0.31 [95% CI 0.14-0.72], p = 0.007) and OS (median 63.3 vs. 32.1 months, unadjusted HR 0.27 [95%CI 0.10-0.68], p = 0.006; aHR 0.32 [95% CI 0.09-1.11], p = 0.072) when compared to no or minimal response (CRS1). CONCLUSIONS: We validate a three-tier CRS for assessment of pathologic response to NACT in OC and demonstrate its prognostic independence of BRCA status or neoadjuvant bevacizumab use. Improving pR rates may be a useful goal of NACT in OC with the expectation of improved survival. The CRS may be a useful endpoint in clinical trials in OC.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Marsh LA, Kim TH, Zhang M, et al. Pathologic response to neoadjuvant chemotherapy in ovarian cancer and its association with outcome: A surrogate marker of survival. Gynecol Oncol. 2023. PMID: 37716223. doi:10.1016/j.ygyno.2023.09.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。